[{"address1": "4-6 Bligh Street", "address2": "Suite 12.01, Level 12", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "phone": "61 2 9423 0881", "fax": "61 2 9423 0881", "website": "https://www.imugene.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 for gastric cancer; VAXINIA is in phase 1 MAST trial for patients with metastatic or advanced solid tumours; and CHECKvacc oncolytic virotherapy is in phase 1 clinical trial against metastatic triple negative breast cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform; and a license agreement with Precision Biosciences Inc. to acquire azer-cell allogeneic CD19 CAR Tcell therapy program. Imugene Limited is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 67, "title": "Executive Chairman", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 208990, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  Chong", "title": "CEO, MD & Executive Director", "fiscalYear": 2023, "totalPay": 696309, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD", "age": 56, "title": "CFO & Company Secretary", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 280510, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.", "title": "Head of Corporate Development", "fiscalYear": 2023, "totalPay": 323610, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Monil  Shah M.B.A., Pharm.D.", "title": "Chief Business Officer", "fiscalYear": 2023, "totalPay": 528389, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bradley  Glover Ph.D.", "age": 54, "title": "Chief Operating Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ursula  McCurry", "title": "Chief Clinical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John  Byon", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph Paul Woodard Jr., M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 9, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.039, "open": 0.04, "dayLow": 0.036, "dayHigh": 0.04, "regularMarketPreviousClose": 0.039, "regularMarketOpen": 0.04, "regularMarketDayLow": 0.036, "regularMarketDayHigh": 0.04, "beta": 3.343, "volume": 190000, "regularMarketVolume": 190000, "averageVolume": 81277, "averageVolume10days": 76261, "averageDailyVolume10Day": 76261, "bid": 0.0359, "ask": 0.045, "marketCap": 291762912, "fiftyTwoWeekLow": 0.02, "fiftyTwoWeekHigh": 0.105, "priceToSalesTrailing12Months": 19.408947, "fiftyDayAverage": 0.0384568, "twoHundredDayAverage": 0.05942395, "currency": "USD", "enterpriseValue": 146693376, "floatShares": 6053218556, "sharesOutstanding": 7481099776, "heldPercentInsiders": 0.08687, "heldPercentInstitutions": 0.06107, "bookValue": 0.027, "priceToBook": 1.4444444, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -89237024, "trailingEps": -0.01, "enterpriseToRevenue": 9.758, "enterpriseToEbitda": -1.636, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IUGNF", "underlyingSymbol": "IUGNF", "shortName": "Imugene, Ltd.", "longName": "Imugene Limited", "firstTradeDateEpochUtc": 1562333400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1cadf534-efa9-3439-bad0-57391ecaca1b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.039, "recommendationKey": "none", "totalCash": 139392032, "totalCashPerShare": 0.019, "ebitda": -89655136, "totalDebt": 6491011, "quickRatio": 5.461, "currentRatio": 5.731, "totalRevenue": 15032392, "debtToEquity": 3.332, "revenuePerShare": 0.002, "returnOnAssets": -0.26146, "returnOnEquity": -0.44370997, "freeCashflow": -46521544, "operatingCashflow": -61250352, "revenueGrowth": 0.676, "grossMargins": 1.0, "operatingMargins": -8.80146, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-08-19"}]